Abstract
Predictions of future clinical applicability of sucralfate are obviously frought with difficulty. Nevertheless, based on the current knowledge of sucralfate’s mode of action, one can envisage several clinical disease states where evaluation of its applicability might be considered useful. Such evaluations would be the more desirable the lesser other therapeutic possibilities are available for both symptomatic and objective improvement of these disease states.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Tarnawski A: Sucralfate. Is it more than just a barrier? Cytoprotection-future direction in prevention and treatment of gastrointestinal mucosal injury. Curr Concepts Gastroenterol 1:5–8, 1984. Superb comprehensive overview of the various mechanisms that are involved in mucosal protection.
Tobiasson P, Stenstam M:Effects of sucralfate and cholestyramine on bile acid absorption. Gaslroenterology 88:393–396, 1985. This study illustrates the bile acid binding capacity of sucralfate.
Scherlacher A, Beaufort-Spontin F: Strahlentherapie von Kopf-Hals-Malignomen: Entzündung-sprophylaxe der Schleimhaut durch Sucralfatbehandlung. HNO 38:24–28, 1990. Oral sucralfate suspension was shown to protect agalnst radiation-induced mucosa injury and symptoms.
Henriksson R, Arevärn M, Frenzen L, et al: Beneficial effects of sucralfate on radiation induced diarrhea. An open randomized study in gynecological cancer patients. Eur J Gynaecol Oncol 11:299–302, 1990. This is one of the first studies on the usefulness of sucralfate in ameliorating the acute radiation effects on the small and large bowel.
Henriksson R, Franzen L, Litbrand B: Effects of sucralfate on acute and late bowel discomfort following radiotherapy of pelvic cancer. J Clin Oncol 10:969–975, 1992. This is one of the rare placebo-controlled studies in a substantial number of patients, supporting the efficacy of sucralfate in acute and late intestinal radiation damage.
Kochhar R, Mehta SK, Aggarwal R, et al:Sucralfate enema in ulcerative rectosigmoid lesions. Dis Colon Rectum 33:49–51, 1990. Sucralfate enemas allow coating of the injured and inflamed mucosa, protecting from luminal irritants and facilitating healing.
Dietrich PY, Forni M Prévention des mucites chimio-induites grâce au sucralfate per os. Bull Cancer 77:613, 1990. Oral sucralfate improves chemotherapy-induced mucosal lesions.
Pfeiffer P, Madsen EL, Hansen O, et al: Effect of prophylactic sucralfate suspension on stomatitis induced by cancer chemotherapy. A randomized, double-blind cross-over study. Acta Oncol 29:171–173, 1990. Radiolabeled sucralfate was shown to adhere to chemotherapy-associated injured buccal mucosa for over 2 hr.
Kotzmann H, Gisslinger H: Treatment and prophylaxis of chemotherapy-induced gastrointestinal complalnts. Results of a pilot study. Proceedings of the Sucralfate Symposium at the European Digestive Disease Week, Amsterdam, 1992. Substantial improvement in nausea and heartburn was obtalned with sucralfate in a large number of patients, treated with chemotherapy.
Shenep JL, Kalwinsky DK, Hutson PR, et al: Efficacy of oral sucralfate suspension in prevention and treatment of chemotherapy-induced mucositis. J Pediatr 113:758–763, 1988. In this study sucralfate falled to improve chemotherapy-induced discomfort but produced colonization of the alimentary tract with pathogens.
Dawson DJ, Khan AN, Miller V, et al: Detection of inflammatory bowel disease in adults and children: Evaluation of a new isotopic technique. Br Med J 291:1227–1230, 1985. This is the first study in IBD where coating of labeled sucralfate of inflamed, denuded intestinal segments was evaluated.
Batman F, Arslan S, Telatar H: Effect of sucralfate in the treatment of solitary rectal ulcer. Endoscopy 20:128, 1988 (Letter). One of the first attempts to improve/heal solitary rectal ulcers is described.
Spilladis C, Skandalis N, Emmanouildis A: Treatment of solitary rectal ulcer syndrome with sucralfate enema. Gastrointest Endosc 35:131–132, 1989. Two patients with solitary rectal ulcer were successfully healed with a sucralfate/glycerine enema.
Zarger SA, Khuroo MS, Mahajan R: Sucralfate retention enemas in solitary rectal ulcer. Dis Colon Rectum 34:455–457, 1991. In this study sucralfate enemas were beneficial in healing solitary rectal ulcers.
Deveaux M, Macalgne O, Lecouffe P, et al: Radioisotopes et entérocolites cryptogénétiques: sucralfate marqué au technétium 99m et granulocytes marqués au tropolonate d’ indium 111. J Med Nuc Biophys 13:139–146, 1989. A poor correlation was found between labeled sucralfate and labeled leukocyte scans.
Mortensen PB, Lech Y, Møller-Petersen J, et al: 99πTc-sucralfate scintigraphy in inflammatory bowel disease. Scand J Gastroenterol 24:1126–1128, 1989. Labeled sucralfate scintigraphy is a poor indicator of disease location.
Zeijen RNM, Van der Pol HAG, Teule GJJ, et al: Sucralphate-technetium scintigraphy in inflamma-tory bowel disease: Experience in 23 patients. Neth J Med 35:76–85, 1989. A poor correlation is described between labeled sucralfate scintigraphy and IBD location in the GI tract.
Zahavi I, Avidor I, Marcus H, et al: Effects of sucralfate in experimental colitis in the rat. Gastroenierology 92:A1707, 1987. Topical administration of sucralfate ameliorates acetic acid-induced colitis in the rat.
Carling L, Kagevi I, Borvall E: Sucralfate enema (SUC)—Effective in IBD? Endoscopy 18:115, 1986. In this open study, almost all patients with UC improved on topical sucralfate therapy.
Bennani A: Utilisation du sucralfate (UlcarR) par voie rectale dans le traltement des localisations distales de la rectocolite hémorragique. M.C.D. 20:181–184, 1991. The treatment of solitary rectal ulcer with sucralfate enemas is described in detall.
Singal AK, Anand BS: Sucralfate in ulcerative colitis. Gastroenterology 9S:A1160, 1989. Topical administration of sucralfate is not efficacious in UC.
Riley SA, Gupta I, Mani V: A comparison of sucralfate and prednisolone enemas in the treatment of active distal ulcerative colitis. Scand J Gastroenterol 24:1014–1018, 1989. Topically applied steroids are superior to sucralfate enemas in distal UC.
Boniface VA, Wright JP, Warner L, et al: Sucralfate enemas in the treatment of ulcerative proctitis. S Afr Med J 80:40, 1991. In this study the usefulness of sucralfate enemas is compared with topical steroids in UC patients. The results are somewhat equivocal.
Campieri M, Gionchetti P, Belluzzi A, et al: Sucralfate, 5-aminosalicylic acid and placebo enemas in the treatment of distal ulcerative colitis. Eur J Gastroenterol Hepatol 3:41–44, 1991. In this well-conducted Italian study, topical sucralfate was clearly shown to be inferior to topical mesalazine therapy in distal UC.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Plenum Press
About this chapter
Cite this chapter
Tytgat, G.N.J. (1995). Future Clinical Development of Sucralfate. In: Hollander, D., Tytgat, G.N.J. (eds) Sucralfate. Springer, Boston, MA. https://doi.org/10.1007/978-0-585-32154-7_33
Download citation
DOI: https://doi.org/10.1007/978-0-585-32154-7_33
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-306-44740-2
Online ISBN: 978-0-585-32154-7
eBook Packages: Springer Book Archive